1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
14
Active Trials
200 recruiting
11
Rare Diseases
across 21 areas
0
News (30d)
Quiet
University of California, Los Angeles is a company with 1 orphan drug designation across 11 rare diseases. Active clinical trials in 14 indications. 10 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Alzheimer disease | - | Des.TrialAppr. |
| Parkinson disease | - | Des.TrialAppr. |
| amyloidosis | - | Des.TrialAppr. |
| cardiovascular disorder | - | Des.TrialAppr. |
| cystic fibrosis | - | Des.TrialAppr. |
| diabetes mellitus | - | Des.TrialAppr. |
| epilepsy | - | Des.TrialAppr. |
| multiple sclerosis | - | Des.TrialAppr. |
| pediatric hepatocellular carcinoma | calcium benzoate and risperidone | Des.TrialAppr. |
| pediatric ovarian dysgerminoma | calcium benzoate and risperidone | Des.TrialAppr. |
| pediatric-onset Graves disease | calcium benzoate and risperidone | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
137
overlap in 2+ diseases
0/11
candidate diseases
0
avg importance: 0
10
affecting portfolio
0% of portfolio targets high unmet need diseases
137
overlap in 2+ diseases
0/11
candidate diseases
0
avg importance: 0
10
affecting portfolio